Suche
Mein Konto
UBS lowers price target for Bayer - uncertainties weigh on shares
UBS lowers its target for Bayer to 32 euros and remains neutral - analysts expect the US legal disputes to have an impact on the shares. Find out more now.
UBS lowers price target for Bayer - uncertainties weigh on shares
The major Swiss bank UBS has lowered the price target for Bayer from 34 to 32 euros due to increased uncertainty regarding the US legal disputes. Despite the lowering of the price target, the rating of Bayer shares was left at “neutral”. These uncertainties, particularly in the company's agricultural chemicals division, are expected to continue to weigh on the share price and be reflected in an increased valuation discount.
Analyst Jo Walton emphasized in a recent study that the uncertainties mentioned were a significant factor in adjusting the price target. The legal disputes in the USA therefore represent a significant challenge for Bayer and could have a negative impact on the company's performance. The impact of these legal disputes on Bayer's financial situation and strategic direction will continue to be closely monitored.
The original study, published on April 12, 2024 at 07:31 GMT, focuses on recent developments related to the US litigation and their potential impact on Bayer. Investors and market observers are therefore closely following the further development of this matter and the company's reactions. Bayer's decisions and actions regarding the litigation will have a significant impact on the future of the company.